01—Abstract
Summary
Summary of the 10-K filed June 23, 2022. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc's (MDT) 10-K filing for the fiscal year ended April 28, 2022, showcases a company rebounding from the COVID-19 pandemic, with net sales reaching $31.7 billiona, a 5% increase year-over-year.
This growth was driven by the recovery of global procedural volumes across its diverse portfolio, which spans Cardiovascular, Medical Surgical, Neuroscience, and Diabetes segments. While overall sales increased, the company navigated challenges including supply chain disruptions, particularly in the latter part of the fiscal year, and the ongoing impact of COVID-19. Medtronic demonstrated solid financial management with free cash flow of $6.0 billionb and continued commitment to shareholder returns through share repurchases and dividends.
The company's strategic focus remains on innovation and market leadership, with significant investment in research and development to drive new product introductions and expand indications. Medtronic's diversified business model, geographic reach, and commitment to its mission of alleviating pain, restoring health, and extending life position it for continued resilience and growth in the global healthcare technology market.
02—Key points
Key Highlights
- Net sales increased by 5% to $31.7 billion, driven by the recovery of global procedural volumes post-COVID-19.
- The Cardiovascular segment saw a 6% increase in net sales, driven by growth in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic divisions.
- The Medical Surgical segment experienced an 11% increase in Surgical Innovations, though overall segment sales grew by 5% due to declines in Respiratory, Gastrointestinal, & Renal.
- Neuroscience sales grew by 7%, with strong performance in Specialty Therapies, partially offset by market dynamics in China.
- The Diabetes segment saw a 3% decrease in net sales, primarily due to U.S. market performance, despite international growth in the MiniMed 780G system.
- Medtronic generated $6.0 billion in free cash flow, demonstrating strong operational cash generation.
- The company repurchased approximately $2.5 billion of its ordinary shares in fiscal year 2022 and had $3.0 billion remaining under its share repurchase authorization.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2022, Medtronic plc kept $0.16.
- Revenue$31.69B100.0%
- Cost of revenue−$10.14B32.0%
- Gross profit$21.54B68.0%
- Operating costs−$15.79B49.8%
- Operating income$5.75B18.2%
- Interest, other & tax−$690.0M2.2%
- Net income$5.06B16.0%
Where FY2022 revenue went
$31.69B- SG&A: $10.29B, 32% of revenue
- Cost of revenue: $10.14B, 32% of revenue
- Other operating costs: $5.50B, 17% of revenue
- Net income: $5.06B, 16% of revenue
- Interest, other & tax: $690.0M, 2.2% of revenue
Kept 16% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2022filed June 23, 2022Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $31.69B$30.12B | +5.2% |
| Cost of Revenue | $10.14B$10.48B | −3.2% |
| Gross Profit | $21.54B$19.63B | +9.7% |
| SG&A Expenses | $10.29B$10.15B | +1.4% |
| Operating Income | $5.75B$4.48B | +28.3% |
| Interest Expense | $553.00M$925.00M | −40.2% |
| Net Income | $5.06B$3.63B | +39.4% |
| EPS (Basic) | $3.75$2.68 | +39.9% |
| EPS (Diluted) | $3.73$2.66 | +40.2% |
| Shares Outstanding (Basic) | 1.34B1.34B | −0.2% |
| Shares Outstanding (Diluted) | 1.35B1.35B | −0.2% |
05—Questions
Frequently Asked Questions
What were the main drivers of Medtronic's revenue growth in fiscal year 2022?
Medtronic's revenue growth in fiscal year 2022 was primarily driven by the recovery of global medical procedure volumes following the impact of the COVID-19 pandemic in the prior year. Key segments like Cardiovascular and Surgical Innovations within Medical Surgical showed strong performance.
What challenges did Medtronic face during fiscal year 2022?
Medtronic faced several challenges, including ongoing global supply chain disruptions, particularly impacting certain product lines in the fourth quarter. The company also noted the continued impact of COVID-19 on procedural volumes and healthcare system staffing shortages, as well as specific market dynamics like lockdowns in China and potential national volume-based pricing tenders in the Neuroscience segment.
How is Medtronic managing its debt and capital resources?
Medtronic maintained a strong liquidity position with $3.7 billion in cash and cash equivalents and $6.9 billion in current investments. The company reduced its total debt to $24.1 billion from $26.4 billion. Medtronic also continued to return value to shareholders through share repurchases, utilizing $3.0 billion of its authorized repurchase program during fiscal year 2022.
What are Medtronic's key strategic priorities moving forward?
Medtronic's strategic priorities include leveraging its pipeline to win market share, accelerating innovation-driven growth, creating and disrupting markets with technology, and empowering its operating units to be more nimble and competitive. The company continues to invest in research and development to bring new technologies and therapies to patients.
06—Continue